Navigating Changes in the U.S. Vaccine Landscape

This document is a report detailing the evolving regulatory landscape for vaccines in the United States. It summarizes a panel discussion that focused on the impact of changes in the CDC and ACIP policies, the challenges faced by vaccine manufacturers, and the need for proactive engagement with various stakeholders. Key developments include a significant overhaul of ACIP membership and substantial cuts in vaccine funding, which have introduced complications in vaccine commercialization. The report outlines the implications of proposed changes such as the potential requirement for placebo-controlled trials and increased safety database requirements for new vaccines. These uncertainties could deter investment in vaccine research and development and affect manufacturers' strategies to secure favorable access for their products. The document emphasizes the necessity for manufacturers to adapt their engagement strategies with medical societies, payer organizations, and governmental stakeholders to maintain vaccine access and adoption in a challenging regulatory environment.